scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0022-5347(05)68632-6 |
P8608 | Fatcat ID | release_m2tkb54f4rbgphzzghrgtzpqfi |
P698 | PubMed publication ID | 10411093 |
P2093 | author name string | Giri D | |
Ittmann M | |||
Ropiquet F | |||
Lamb DJ | |||
P433 | issue | 2 | |
P921 | main subject | prostatic hypertrophy | Q506659 |
P304 | page(s) | 595-599 | |
P577 | publication date | 1999-08-01 | |
P1433 | published in | Journal of Urology | Q15709979 |
P1476 | title | FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation | |
P478 | volume | 162 |
Q37281184 | A signaling network in phenylephrine-induced benign prostatic hyperplasia |
Q36331201 | Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia |
Q31912970 | Alternative splicing of fibroblast growth factor receptors in human prostate cancer |
Q33520245 | Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer |
Q43693825 | Basic fibroblast growth factor and keratinocyte growth factor over-expression in benign prostatic hyperplasia |
Q34057789 | Cultured stromal cells: an in vitro model of prostatic mesenchymal biology |
Q38915711 | Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets |
Q61798949 | Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia |
Q28144257 | FGF-10 is expressed at low levels in the human prostate |
Q52723926 | Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN. |
Q28215493 | Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis |
Q36390245 | Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting |
Q37258877 | Growth factors in benign prostatic hyperplasia: basic science implications |
Q35745901 | Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia |
Q35747214 | Interleukin-6 is an autocrine growth factor in human prostate cancer. |
Q35746575 | Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia |
Q39914178 | Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model |
Q39825713 | Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. |
Q38210468 | Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors |
Q54410051 | Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix. |
Q38363715 | Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo |
Q92030387 | Stimulation of Prostate Cells by the Senescence Phenotype of Epithelial and Stromal Cells: Implication for Benign Prostate Hyperplasia |
Q35640720 | Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor |
Q41840130 | The senescence-associated secretory phenotype promotes benign prostatic hyperplasia |
Q89851597 | Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia |
Q77359737 | Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate |
Q52588865 | [Pathophysiology and therapy of benign prostatic hyperplasia]. |
Search more.